ライフサイエンスコーパス: cell immunity

1 an innate link between viral infection and B cell immunity.

2 class II expression, suggesting a role in T cell immunity.

3 fiers to explore the long-term dynamics of T cell immunity.

4 immunogenicity for inducing antibodies and T cell immunity.

5 development of vaccines that evoke optimal T cell immunity.

6 d qualitatively altered YF-specific CD4(+) T cell immunity.

7 ing as a viable approach to augment CD8(+) T-cell immunity.

8 udies unveil an essential role of Gpx4 for T cell immunity.

9 pecific subsets of dendritic cells and CD8 T cell immunity.

10 y bowel disease-all with severely impaired T-cell immunity.

11 ter with a conditioning regimen to restore B-cell immunity.

12 inadequacy to evade HLA-A*02:01-restricted T-cell immunity.

13 ubjects has a significant effect on T- and B-cell immunity.

14 t peptide is virtually unable to stimulate T cell immunity.

15 01 molecule, and play an important role in T-cell immunity.

16 immunoregulatory cytokine IL-10 suppresses T-cell immunity.

17 okine family involved in the regulation of B-cell immunity.

18 characterized by their ability to inhibit T cell immunity.

19 of Th17 cells to preserve an effective HIV T-cell immunity.

20 survival by inducing robust tumor-specific T-cell immunity.

21 verlapping and yet distinct mucosal and DC/T cell immunity.

22 re considered to play little or no role in T cell immunity.

23 l strategy to harness endogenous antitumor T-cell immunity.

24 broad spectrum of biological processes of T cell immunity.

25 sm with superior long-term recovery of CD4 T-cell immunity.

26 tion immunotherapies that can fully engage T-cell immunity.

27 rmation of resident versus nonresident CD8 T cell immunity.

28 cells into strategies designed to enhance T cell immunity.

29 ody responses, we found key differences in T-cell immunity.

30 entation by pDCs in driving proatherogenic T cell immunity.

31 NPs to distinct DC subsets led to enhanced T cell immunity.

32 ich is critically dependent on Ag-specific T cell immunity.

33 nstrate the role of FA synthesis in CD8(+) T cell immunity.

34 dies of the role of RAR isoforms in CD8(+) T cell immunity.

35 the host to mount effective antiviral CD8 T cell immunity.

36 mune tolerance and tips the balance toward T cell immunity.

37 employed cytokines; and (4) activators of T cell immunity.

38 n vaccines capable of eliciting protective B-cell immunity.

39 val is dependent on their ability to evade T-cell immunity.

40 ols to establish lifelong antigen-specific T-cell immunity.

41 matory responses and in the suppression of T cell immunity.

42 genic state and promote the development of T cell immunity.

43 or the generation of virus-specific CD8(+) T cell immunity.

44 tuberculosis, but other diseases requiring T cell immunity.

45 n that influence memory formation and CD8+ T cell immunity.

46 ir JAK/STAT pathways play pivotal roles in T cell immunity.

47 action is pivotal in all aspects of CD8(+) T-cell immunity.

48 that P. aeruginosa induces MDSCs to escape T cell immunity.

49 independent of vaccine-specific B-cell or T-cell immunity.

50 ted their suppressive properties to induce T cell immunity.

51 on to generate protective antiviral CD8(+) T-cell immunity.

52 tations of human fetal and neonatal CD4(+) T cell immunity.

53 hrough balanced induction of Treg versus Th2 cell immunity.

54 ed the mechanisms involved in LSEC-induced T cell immunity.

55 iving forces behind the influenza-specific B-cell immunity.

56 novel VZV vaccines that specifically boost T cell immunity.

57 me and boost for generating optimal CD8(+) T cell immunity.

58 wn about the mechanisms of LSECs to induce T cell immunity.

59 e the magnitude, quality, and phenotype of T cell immunity.

60 re-existing or treatment-induced antitumor T-cell immunity.

61 D152) that acts as a negative regulator of T cell immunity.

62 and peripheral tolerance than in effector T cell immunity.

63 important functions of EBF1 in controlling B cell immunity.

64 sease and the regulation of virus-specific T cell immunity.

65 e divergent in the costimulation of CD4(+) T cell immunity.

66 ed to impede the development of protective B cell immunity.

67 city and sensitivity in mediating adaptive T-cell immunity.

68 central correlates of T cell tolerance and T cell immunity.

69 coexpressing CD4 helper cells in antiviral B cell immunity.

70 s but did not explain the defect in CD8(+) T cell immunity.

71 s are an essential component of long-lived T cell immunity.

72 critical for the generation of protective T cell immunity.

73 eous and PD-L1-blockade-mediated antitumor T cell immunity.

74 ed partly on induction of sustainable host T-cell immunity.

75 d "atypical" SCID show reduced, not absent T-cell immunity.

76 ction of IL-1beta, and defective antiviral T cell immunity.

77 r sterols and oxysterols in macrophage and T-cell immunity.

78 review examines the effects of MS DMTs on B-cell immunity.

79 ire is fundamental to our understanding of B-cell immunity.

80 and atg5 in regulating TLR signalling and B-cell immunity.

81 subsets that likely compromise anti-tumor T cell immunity.

82 en-presenting cells to stimulate antitumor T-cell immunity.

83 the generation of an optimal effector CD8 T cell immunity.

84 epsis might facilitate the recovery of CD8 T cell immunity.

85 as associated with enhanced virus-specific T-cell immunity.

86 lay an important role in the regulation of B-cell immunity.

87 nd inhibits formation of pathogen-specific T cell immunity.

88 TP on innate proinflammatory responses and T-cell immunity.

89 , suggesting interference of carriage with T-cell immunity.

90 fied E2A and E2-2 as central regulators of B cell immunity.

91 nism involving the inhibition of antitumor T-cell immunity.

92 facilitates the emergence of potent CD8(+) T-cell immunity able to durably suppress virus replication

93 n single lymphoma nodes, mediated systemic T-cell immunity accompanied by regression of disseminated

94 Quantifying CMV-specific T-cell immunity after HSCT can identify participants at in

95 lung DCs abrogated the induction of CD8(+) T cell immunity after immunization with particulate antige

96 critical for the generation of robust CD8+ T-cell immunity after s.s. with VACV.

97 ure to achieve reconstitution of antiviral T-cell immunity after SCT.

98 ween DC dysfunction and impairments in CD8 T cell immunity after sepsis by directly targeting Ag to D

99 al strategies for generating heterogeneous T-cell immunity against cancer, with the appropriate balan

100 be possible to generate broadly protective T-cell immunity against commonly occurring virus escape mu

101 We previously described CD4(+) T-cell immunity against HBsAg and polymerase in chimpanzee

102 ts potential for triggering protective CD8 T cell immunity against heterologous influenza virus chall

103 Induction of B-cell immunity against infection depends on the initiatio

104 g cell motility are essential for adaptive T-cell immunity against infectious pathogens and cancers.

105 that dendritic cells help CD4(+) T helper 1 cell immunity against malaria through PD-L2's competitio

106 pensable for establishing effective CD4(+) T cell immunity against malaria, because it not only inhib

107 restoration of intrahepatic CD4+ and CD8+ T-cell immunity against multiple HCV proteins.

108 T-cell immunity against stem-cell antigen SOX2 and preserv

109 ss of GCIPL is associated with intrathecal B-cell immunity and constitutes an independent risk factor

110 Induction of antiviral CD8(+) T-cell immunity and cytotoxicity was documented in WAS KO

111 recently been shown to correlate with anti T-cell immunity and efficacy of checkpoint inhibitor thera

112 The contribution of host T-cell immunity and HLA class I alleles to the control of

113 the current understanding of HIV-specific T-cell immunity and identify cellular immune responses and

114 phase augmented DC vaccine-induced CD8(+) T-cell immunity and improved antitumor efficacy, suggestin

115 acute stages of sepsis develop compromised T cell immunity and increased susceptibility to infection.

116 a critical immune regulator by suppressing T cell immunity and macrophage activation during inflammat

117 to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveill

118 key discoveries in the area of flavivirus T cell immunity and postulate on how these findings can in

119 pressing macrophages that inhibited CD8(+) T cell immunity and promoted CD4(+)Foxp3(+) Treg cell expa

120 osinic-polycytidylic acid (poly IC) on CD8 T cell immunity and protection elicited by LAIVs.

121 of various TLR ligands on SIV Gag-specific T cell immunity and protection following prime-boost immun

122 ch is a prerequisite for successful CD8(+) T-cell immunity and protective vaccination, can only be ac

123 Here, CD8+ T-cell immunity and response to reinfection were assessed

124 aemia, which leads to the establishment of T-cell immunity and resultant long-term infection control.

125 nses results in significant alterations in T cell immunity and subsequent disease outcome upon reexpo

126 ib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade

127 zed antigen-presenting cells that initiate T cell immunity and tolerance.

128 allele predicted resurgent virus-specific T-cell immunity and viral control at 3-mo postpartum (P =

129 ur understanding of the interplay between NK cell immunity and viral pathogenesis has improved signif

130 cations in the investigations on cancer stem cells, immunity and immune modulators, applications with

131 ute infectious agents induce strong CD8(+) T cell immunity, and are thought to therefore represent a

132 ndritic cells (DCs) are potent inducers of T cell immunity, and autologous DC vaccination holds promi

133 4 mAbs elicited combined CD4(+) and CD8(+) T cell immunity, and both T cells participated in resistan

134 cts the spread of virus infection, optimal B cell immunity, and disease pathogenesis.

135 , these T cells support engraftment, early T-cell immunity, and mediate the graft-versus-tumor (GVT)

136 ve Th17 polarization and influence mucosal T-cell immunity, and suggest that host pathways to handle

137 contributes to the observed defects in CD8 T cell immunity, and therapeutic approaches designed to im

138 tions, and new vaccines that induce CD8(+) T cell immunity are currently needed.

139 (TNFR)-associated factor (TRAF) family in T cell immunity are not well understood.

140 The study of T cell immunity at barrier surfaces has largely focused on

141 HSCT recipients we evaluated CMV-specific T-cell immunity at baseline, 3, 6, 9, and 12 months after

142 se among those infected, but the impact of T-cell immunity at the population level is unknown.

143 signaling also has been shown to regulate T cell immunity, but its sites and mechanism of action in

144 ve a negative impact on the development of T-cell immunity by using the murine lymphocytic choriomeni

145 Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfected

146 to successful and sustained restoration of T-cell immunity correlated with virologic response and pro

147 s from HPV-16 E6/E7 for which induction of T-cell immunity correlates with disease-free survival in p

148 evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Pers

149 The fidelity of T cell immunity depends greatly on coupling T cell recepto

150 ) mice were deficient in generating CD8(+) T-cell immunity despite normal clonal expansion, likely du

151 reover, we advocate that tumor Ag-specific T cell immunity directed against self-proteins can be expl

152 T cell immunity directed against tumor-encoded amino acid

153 ng imply that exosomes function to promote T cell immunity during a bacterial infection and are an im

154 l a mechanism by which S. Typhi may target T-cell immunity during establishment of typhoid.

155 his study, we analyzed the role of IAPs in T-cell immunity during lymphocytic choriomeningitis virus

156 Thus, maternal CD4(+) T-cell immunity during primary rhCMV infection is importan

157 undamental role in the induction of CD8(+) T cell immunity during viral, intracellular bacterial, and

158 tions about the establishment of effective B cell immunity elicited by vaccination, not just against

159 cytogenes (which induces CD4(+) and CD8(+) T-cell immunity) engineered to express Kras(G12D) (LM-Kras

160 noviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch bet

161 cident with development of strain-specific T-cell immunity followed by emergence of cross-reactive vi

162 test to identify recovery of CMV-specific T-cell immunity following hematopoietic stem cell transpla

163 importance of functional PMN, T-cell, and NK-cell immunity for the outcome of IA.

164 Thus, B-cell immunity frequently targets cryptotopes on CMV but

165 Thus, CD8(+) T cell immunity generated during primary DENV infection ca

166 1(+) DCs in determining the type of CD8(+) T cell immunity generated to live-attenuated influenza vir

167 T-cell immunity has been linked to the exceptional outcome

168 Restoration of antigen-specific T cell immunity has the potential to clear persistent vira

169 dies (mAbs) able to reinvigorate antitumor T-cell immunity have heralded a paradigm shift in cancer t

170 ould be targeted for optimal activation of T cell immunity, however, remains unknown.

171 rrent helminth infection potently inhibits T cell immunity; however, whether helminthes prevent T cel

172 prospectively analyzed antigen-specific B/T-cell immunity, immune composition of the tumor microenvi

173 valuated peripheral blood and lung mucosal T-cell immunity in 14 HIV(+)COPD(+), 13 HIV(+)COPD(-), and

174 mportant studies on the function of T- and B-cell immunity in atherosclerosis and their manipulation

175 While T cell immunity in brucellosis has been extensively studie

176 f these DC subsets to boost tumor-reactive T cell immunity in cancer patients.

177 oducing subset of B cells able to regulate T cell immunity in CHB.

178 or (TCR) gene therapy can reconstitute CD8 T cell immunity in chronic patients.

179 there has been debate about centrality of T cell immunity in defense, these observations support a r

180 understanding the correlates of protective T cell immunity in HIV infection, the optimal approach to

181 HLA class II alleles and then assessed CD4 T cell immunity in HLA class II transgenic mice and in ser

182 ed signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown.

183 f therapeutic type 1 antigen-specific CD8+ T cell immunity in humans with cancer.

184 a, due to their ability to potently induce T cell immunity in humans.

185 therefore a novel functional component of T-cell immunity in latent TB and potential correlate of pr

186 ic cells (DCs) prime and orchestrate naive T cell immunity in lymphoid organs, but recent data also h

187 ections support the clinical importance of T-cell immunity in mediating protective antiviral effects.

188 class II heterodimers and stimulate strong T cell immunity in mice and humans.

189 fine antigenic epitopes determining CD8(+) T cell immunity in murine models of ZIKV infection.

190 sults suggest that IL-10 suppresses CD4(+) T-cell immunity in nonvaccinated mice during Coccidioides

191 This investigation of virus-specific T-cell immunity in patients with HDV infection, the larges

192 isplay diminished capacity for controlling T cell immunity in prostate inflammation and cancer models

193 nimals, indicating a minimal role for CD4+ T-cell immunity in rVSV-mediated protection.

194 tributing factor leading to diminished CD8 T cell immunity in septic hosts.

195 for vaccines and/or therapies that require T cell immunity in the lung.

196 (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been described.

197 n of TSLP levels may promote long-term CD8 T cell immunity in the mucosa when other prosurvival signa

198 tor and the cytokine IL-2, but its role in T-cell immunity in vivo has not been explored.

199 Instead, its effect on T cell immunity in vivo may involve CD11b(+)F4/80(+) or ot

200 be of significant importance in regulating T-cell immunity in vivo.

201 eficiencies are marked by inborn errors of T-cell immunity in which the T cells that are present are

202 gies, the therapeutic goal is to re-ignite T-cell immunity, in order to eradicate tumors.

203 e we discuss new approaches to probe human T cell immunity, including novel sampling, that indicate a

204 One possibility is that T cell immunity incorporates an extremely high level of re

205 Identification of positive regulators of T-cell immunity induced during autoimmune diseases is crit

206 he efficient induction of stable antiviral T cell immunity irrespective of the nature of the antigeni

207 Reconstitution of T cell immunity is absolutely critical for the effective c

208 Induction of proinflammatory T cell immunity is augmented by innate dendritic cell (DC)

209 ticular, IFN-gamma-polarized cytotoxic CD8 T cell immunity is considered optimal for protective immun

210 T-cell immunity is critical for control of CMV infection,

211 tocompatibility complex class I-restricted T-cell immunity is essential to control infection with cyt

212 minimal thresholds for effective antiviral T cell immunity is important for clinical decisions in imm

213 T-cell immunity is important for controlling Kaposi sarcom

214 tion against reinfection and that adaptive T cell immunity is important for viral clearance.

215 tment for malaria and other diseases where T cell immunity is ineffective or short-lived due to PD-1-

216 ration, suggesting that Arg1 regulation of T-cell immunity is involved in disease control.

217 T cell immunity is often defined in terms of memory lympho

218 ery of IL-1beta to determine that adaptive T cell immunity is required for airway remodeling because

219 An important question is whether T-cell immunity is sufficiently strong to drive influenza

220 Thus, eliciting robust CD8 T-cell immunity is the basis for many vaccines under devel

221 f IFN-gamma in tuberculosis (TB), and CD4+ T cell immunity is the main target of current TB vaccine c

222 Adaptive CD8 T-cell immunity is the principal arm of the cellular alloi

223 cell antigen presentation, but its role in T-cell immunity is unknown.

224 T cell immunity is vital for the control of KSHV infection

225 A characterization of RSV-specific T-cell immunity is warranted.

226 importance of the immune adaptor SLP-76 in T-cell immunity, it has been unclear whether SLP-76 direct

227 kine pathway is critical in shaping CD8(+) T cell immunity, locally within latently infected tissues,

228 standing of how the existing DMTs modulate B-cell immunity may identify future targets for therapeuti

229 but it is unknown whether disturbances to T cell immunity may render these patients vulnerable to fu

230 mmunogenic cell death, which could trigger T-cell immunity mediated by high-mobility group box 1 prot

231 T-cell immunity might be an essential component of safe, e

232 hanced dengue infections suggest that poor T-cell immunity might have contributed to protection failu

233 of whether preexisting dengue virus (DENV) T cell immunity modulates these responses.

234 cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of grea

235 , we evaluated the contributions to CD8(+) T cell immunity of CD40 expressed on host tissues includin

236 e a dual impact of host adaptive antitumor T-cell immunity on the clinical effectiveness of rapalogs

237 ve generally focused on either stimulating T cell immunity or driving antibody-directed effector func

238 ction, pDCs can also process Ag and induce T cell immunity or tolerance.

239 We assessed whether vaccine-induced T-cell immunity, or expression of certain HLA alleles, imp

240 cal observations suggest that VZV-specific T cell immunity plays a more critical role than humoral im

241 Ab-mediated protection, the role that CD8 T cell immunity plays in overall VLP-mediated protection i

242 s study, we sought to investigate the role T cell immunity plays in recognizing and controlling genet

243 the evidence of IL-33 to drive protective T cell immunity plus its potential use as an adjuvant in v

244 Naturally occurring cross-protective T-cell immunity protects against symptomatic PCR-confirmed

245 PO-R signaling on T cells to inhibition of T-cell immunity, providing one mechanism that could explai

246 t lead to improved Ag presentation and CD8 T cell immunity; rather, it recruited FcgammaR-bearing inn

247 if this observed immunoparalysis of CD8(+) T cell immunity recovers, and the long-term consequences o

248 rocesses involved in generation of durable T-cell immunity remain undefined.

249 T-cell immunity requires extremely rapid clonal proliferat

250 However, current LAIVs exert limited T cell immunity restricted to the vaccine strains.

251 Absent T-cell immunity resulting in life-threatening infections p

252 Mouse studies of T cell immunity show that, in response to infection, T cel

253 f B cells in TB vaccine-induced protective T cell immunity still remains unknown.

254 parameters of M. tuberculosis-specific CD4 T cell immunity that are impaired in HIV-infected individu

255 in MS but represent a component of active B cell immunity that is dynamically supported on both side

256 (LAIVs) have the potential to generate CD8 T cell immunity that may limit the virulence of an antigen

257 ut elicited a systemic Foxp3(+) CD25(+) Treg cell immunity that suppressed diabetes induction by a su

258 lated with high antibody titers yet CD4(+) T cell immunity that was significantly less potent than th

259 the importance of the co-receptor PD-1 in T cell immunity, the upstream signaling pathway that regul

260 mice with rLm/iglC significantly enhanced T cell immunity; their splenic T cells secreted significan

261 ecruitment of mast cells and activation of T cell immunity through C3a are important for parasite con

262 novel insights into how viruses can evade NK cell immunity through the selection of mutations in HLA-

263 nse, these observations support a role for T cell immunity to AhpC in disease protection.

264 of 7 treated patients developed sustained T cell immunity to all 3 melanoma gp100 antigen-derived pe

265 allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin.

266 n neonates have reduced and delayed CD4(+) T cell immunity to certain pathogens, but the mechanisms f

267 se data indicate that protective antiviral T-cell immunity to CMV is generated by direct presentation

268 us (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses re

269 T cell immunity to GroEL (BPSL2697) was specifically impai

270 Studies of T-cell immunity to human cytomegalovirus (CMV) primarily r

271 pitope recognition by CD8(+)T cells, CD4(+)T cell immunity to KSHV may be important for maintaining t

272 culosis infection, and in the evolution of T-cell immunity to M. tuberculosis in response to tubercul

273 eptor 3 (CXCR3) chemokine pathway promotes T cell immunity to many viral pathogens, but its importanc

274 for p110delta signaling in in vivo CD8(+) T cell immunity to microbial pathogens.

275 responder animal had a history of broader T-cell immunity to multiple HCV proteins than the two chim

276 Survival was associated with enhanced T cell immunity to nine of fifteen immunodominant antigens

277 dogenous NK cell and tumor Ag-specific CD8 T cell immunity to provide a marked reduction in tumor bur

278 al pathogens, but its importance in CD8(+) T cell immunity to recurrent herpes has been poorly elucid

279 modifying therapies (DMTs) for MS modulate B-cell immunity to some degree.

280 trafficking may impact the development of B-cell immunity to systemic viral pathogens.

281 stance may provide insight into protective T cell immunity to TB.

282 presentation, leading to the paradigm that T-cell immunity to these pathogens necessitates cross-pres

283 nhances the human NoV-specific mucosal and T cell immunities triggered by a VSV-based human NoV vacci

284 hocytes, are critical for the induction of B cell immunity upon viral infection.

285 associated with more pronounced antitumor T-cell immunity via induction of IL17 and IFNgamma-produci

286 ain-containing molecule 4 (Tim4) regulates T-cell immunity via phagocytosis of both apoptotic (high P

287 on; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-programm

288 thesis that impaired human neonatal CD4(+) T cell immunity was due to reduced signaling by naive CD4(

289 The LSEC-mediated CD8(+) T cell immunity was initiated by soluble mediators, one of

290 ound negative effect of IAP antagonists on T-cell immunity was partially linked to tumor necrosis fac

291 enetic diagnosis nor basic measurements of T-cell immunity were good predictors of disease evolution.

292 successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic dr

293 endritic cells (DCs) is required to induce T cell immunity, whereas immature DCs can induce immune to

294 onverge on NFATc1 with opposing effects on T cell immunity, which may underlie the beneficial effect

295 n a lack of activation of antigen-specific T-cell immunity, which plays an important role in protecti

296 ic CD4(+) T-cell compartment that suppress T-cell immunity while concomitantly promoting aberrant IgG

297 of which is necessary for preservation of T cell immunity while suppressing tissue damage.

298 ide criteria for optimizing protective CD8 T cell immunity with rAd vaccines.

299 ioning regulates the extent and quality of T cell immunity, with important implications for vaccine d

300 These results imply an ongoing beta cell immunity years after onset of diabetes and suggest